Antonino Catalano1,2, Gabriella Martino3, Federica Bellone4, Maria Papalia4, Carmen Lasco4, Giorgio Basile4, Alberto Sardella4, Giacomo Nicocia4, Nunziata Morabito4, Antonino Lasco4. 1. Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy. catalanoa@unime.it. 2. Department of Clinical and Experimental Medicine, University Hospital "G. Martino", Via C. Valeria, 98125, Messina, Italy. catalanoa@unime.it. 3. Department of Cognitive Sciences, Psychology, Education and Cultural Studies, University of Messina, Messina, Italy. 4. Department of Clinical and Experimental Medicine, University Hospital of Messina, Messina, Italy.
Abstract
BACKGROUND AND OBJECTIVE: Benign prostatic hyperplasia (BPH) is a common disease found in elderly men and 5α-reductase (5α-R) inhibitors are a commonly used treatment option. 5α-reduced steroids are compounds that play a role in several functions across different organs and systems. In the adult brain, 5α-R accounts for neuroactive steroid production. Whether neuropsychological impairment could be due to dutasteride treatment, a 5α-R inhibitor affecting the production of dihydrotestosterone (DHT), is still unknown. The aim of our study was to investigate neuropsychological features in men receiving dutasteride. METHODS: The Mini Mental State Examination (MMSE), the Clock Drawing Test (CDT), the Frontal Assessment Battery (FAB), the Hamilton Anxiety Rating Scale (HAM-A), the Beck Depression Inventory second edition (BDI-II) and the Short Form-12 (SF-12) questionnaire were administered in order to explore both cognitive impairment and psychological features. RESULTS: In a sample of BPH patients (n = 40; mean age 71.4 ± 7.4 years), men receiving dutasteride showed no significant differences during the neuropsychological assessment in comparison with an age-matched control group, consisting of BPH men not receiving dutasteride (p < 0.05). No significant associations were recorded between treatment duration and any of the administered tests. CONCLUSIONS: This is the first study investigating the neuropsychological features in dutasteride users. Our preliminary data are consistent with the safety of dutasteride under a mental profile.
BACKGROUND AND OBJECTIVE:Benign prostatic hyperplasia (BPH) is a common disease found in elderly men and 5α-reductase (5α-R) inhibitors are a commonly used treatment option. 5α-reduced steroids are compounds that play a role in several functions across different organs and systems. In the adult brain, 5α-R accounts for neuroactive steroid production. Whether neuropsychological impairment could be due to dutasteride treatment, a 5α-R inhibitor affecting the production of dihydrotestosterone (DHT), is still unknown. The aim of our study was to investigate neuropsychological features in men receiving dutasteride. METHODS: The Mini Mental State Examination (MMSE), the Clock Drawing Test (CDT), the Frontal Assessment Battery (FAB), the Hamilton Anxiety Rating Scale (HAM-A), the Beck Depression Inventory second edition (BDI-II) and the Short Form-12 (SF-12) questionnaire were administered in order to explore both cognitive impairment and psychological features. RESULTS: In a sample of BPH patients (n = 40; mean age 71.4 ± 7.4 years), men receiving dutasteride showed no significant differences during the neuropsychological assessment in comparison with an age-matched control group, consisting of BPH men not receiving dutasteride (p < 0.05). No significant associations were recorded between treatment duration and any of the administered tests. CONCLUSIONS: This is the first study investigating the neuropsychological features in dutasteride users. Our preliminary data are consistent with the safety of dutasteride under a mental profile.
Authors: B I Weinstein; N Kandalaft; R Ritch; C B Camras; D J Morris; S A Latif; P Vecsei; J Vittek; G G Gordon; A L Southren Journal: Invest Ophthalmol Vis Sci Date: 1991-06 Impact factor: 4.799
Authors: Ciro Conversano; Mariagrazia Di Giuseppe; Mario Miccoli; Rebecca Ciacchini; Annarita Di Silvestre; Rosa Lo Sterzo; Angelo Gemignani; Graziella Orrù Journal: Clin Neuropsychiatry Date: 2020-08